Health Insurance Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cyprotex
Cyprotex launches mechanism-based inhibition of cytochrome P450 screening service
August 13th, 2006
Cyprotex announced the launch of its new screening service, designed to help drug discovery teams identify compounds which are mechanism-based inhibitors of cytochrome P450 (CYP450). The inhibition of human CYP450s is one of the most common mechanisms which can lead to drug-drug interactions. Metabolic drug-drug interactions, following the co-administration of drugs, can result in either reduced efficacy or increased toxicity. Screening for mechanism-based inhibition of CYP450 earlier in the drug discovery process enables researchers to determine and advance only the compounds which avoid such liabilities, thereby reducing the possibility of costly late-stage...
Source: Health Insurance Law Weekly (2006-08-13)
|
